Châtillon, France, May 30, 2024
DBV Technologies to Participate in
Upcoming EAACI 2024 Congress
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company focused on treatment options for food
allergies and other immunologic conditions with significant unmet
medical need, today announced its upcoming participation in the
European Academy of Allergy and Clinical Immunology (EAACI)
Congress May 31 – June 3 in Valencia, Spain.
A flash talk presentation by Nicolette Arends,
M.D., Erasmus University Rotterdam will describe data collected on
accidental peanut consumption from DBV’s EPITOPE Phase 3 study and
its ongoing open-label extension study in peanut-allergic toddlers
aged 1 through 3 years. DBV will also host a symposium and exhibit
booth in the EAACI exhibit hall.
“We are deeply committed to establishing
long-term safety and clinical data of Viaskin Peanut in the
pediatric population, which includes examining reactions that occur
during accidental consumption,” said Daniel Tassé, Chief Executive
Officer of DBV Technologies. “While avoidance is the first line of
defense, the reality is an accidental exposure is likely,
necessitating approved treatment options that can help provide
protection.”
“We track accidental peanut consumption in our
clinical studies to better understand how epicutaneous
immunotherapy with Viaskin Peanut may help reduce the risk of an
allergic reaction over time,” said Pharis Mohideen, M.D. Chief
Medical Officer at DBV Technologies. “Analyzing accidental peanut
consumption exposure better characterizes the real-world clinical
benefit that Viaskin Peanut may provide if approved.”
DBV’s symposium, “Epicutaneous Route: An
Innovative Potential Approach to Food Immunotherapy”, will be
moderated by Stefania Arasi, M.D., Ph.D., MSc., Pediatric Allergist
and Researcher at Paediatric Allergy Unit, Bambino Gesù Children
Research Hospital, Rome, Italy and current EAACI Pediatric Section
Chair and Philippe Eigenmann, M.D., Pediatric Allergist and Head of
Pediatric Allergy Unit at the Geneva University Hospital, Geneva,
Switzerland. It will include lectures by Luciana Tanno, M.D., Ph.D.
Allergist, Division of Allergy, University Hospital of Montpellier,
Montpellier, France on potential clinical applications of the
epicutaneous route, and Pablo Rodríguez del Río, M.D., Ph.D.,
Allergist Hospital Infantil Universitario Niño Jesús, Department of
Allergy, Madrid, Spain, on most recent results and perspectives of
the epicutaneous route in peanut allergy, respectively.
DBV will host a booth (F10) in the exhibit hall
where attendees can learn more about epicutaneous immunotherapy
with Viaskin, including our ongoing clinical trials in
peanut-allergic children.
Flash Talk Presentation
Details
“Reactions Due to Accidental Peanut
Consumption During Epicutaneous Immunotherapy for Peanut Allergy in
Toddlers” presented by Nicolette Arends, M.D. Researcher,
Pediatrics Erasmus University Medical Center, Rotterdam,
Netherlands
- Session title: Flash Talks on
Pediatrics
- Session number: FT 15
- Session date: Sunday, June 2,
2024
- Session time: 8:30 a.m. – 10:30
a.m. CET
A voice-recording of the onsite flash talk
presentation will be made available on the congress platform. A
copy of the poster will be made available after the presentation on
the Scientific Publications & Presentations page on the Our
Science section of the Company’s website
www.dbv-technologies.com.
Symposium
“Epicutaneous route: An innovative
potential approach to food immunotherapy” will be
moderated by Stefania Arasi and Philippe Eigenmann
- Date and location: Saturday, June
1, 12:00 – 1:00 p.m. CEST, Malaga Room
- Lectures:
- Introduction- Dr.
Stefania Arasi
- The epicutaneous route:
from the concept to potential clinical applications- Dr.
Luciana Tanno
- The epicutaneous
immunotherapy for peanut allergy: most recent results and
perspectives- Dr. Pablo Rodríguez del Río
- Conclusion- Dr.
Philippe Eigenmann
About DBV TechnologiesDBV
Technologies is a clinical-stage biopharmaceutical company
developing treatment options for food allergies and other
immunologic conditions with significant unmet medical need. DBV is
currently focused on investigating the use of its proprietary
technology platform, Viaskin™, to address food allergies, which are
caused by a hypersensitive immune reaction and characterized by a
range of symptoms varying in severity from mild to life-threatening
anaphylaxis. Millions of people live with food allergies, including
young children. Through epicutaneous immunotherapy (EPIT™), the
Viaskin platform is designed to introduce microgram amounts of a
biologically active compound to the immune system through intact
skin. EPIT is a new class of non-invasive treatment that seeks to
modify an individual’s underlying allergy by re-educating the
immune system to become desensitized to allergen by leveraging the
skin’s immune tolerizing properties. DBV is committed to
transforming the care of food allergic people. The Company’s food
allergy programs include ongoing clinical trials of Viaskin Peanut
in peanut allergic toddlers (1 through 3 years of age) and children
(4 through 7 years of age).
DBV Technologies is headquartered in Châtillon,
France, with North American operations in Warren, NJ. The Company’s
ordinary shares are traded on segment B of Euronext Paris (Ticker:
DBV, ISIN code: FR0010417345) and the Company’s ADSs (each
representing one-half of one ordinary share) are traded on the
Nasdaq Stock Market (Ticker: DBVT).
For more information, please visit
www.dbv-technologies.com and engage with us on X (formerly Twitter)
and LinkedIn.
Forward Looking StatementsThis
press release may contain forward-looking statements and estimates,
including, but not limited to, statements regarding the therapeutic
potential of Viaskin™ Peanut and EPIT™ and DBV’s planned regulatory
and clinical efforts including timing and results of communications
with regulatory agencies, and the ability of any of DBV’s product
candidates, if approved, to improve the lives of patients with food
allergies. These forward-looking statements and estimates are not
promises or guarantees and involve substantial risks and
uncertainties. At this stage, DBV’s product candidates have not
been authorized for sale in any country. Among the factors that
could cause actual results to differ materially from those
described or projected herein include uncertainties associated
generally with research and development, clinical trials and
related regulatory reviews and approvals, and DBV’s ability to
successfully execute on its budget discipline measures. A further
list and description of risks and uncertainties that could cause
actual results to differ materially from those set forth in the
forward-looking statements in this press release can be found in
DBV’s regulatory filings with the French Autorité des Marchés
Financiers (“AMF”), DBV’s filings and reports with the U.S.
Securities and Exchange Commission (“SEC”), including in DBV’s
Annual Report on Form 10-K for the year ended December 31, 2023,
filed with the SEC on March 7, 2024, and future filings and reports
made with the AMF and SEC by DBV. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements and estimates, which speak only as of
the date hereof. Other than as required by applicable law, DBV
Technologies undertakes no obligation to update or revise the
information contained in this Press Release.
Viaskin and EPIT are trademarks of DBV
Technologies.
Investor Contact Katie
MatthewsDBV Technologieskatie.matthews@dbv-technologies.com
Media ContactAngela MarcucciDBV
Technologiesangela.marucci@dbv-technologies.com
DBV Technologies (EU:DBV)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 12월(12) 2024
DBV Technologies (EU:DBV)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
